CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR-T therapy for gastrointestinal cancers: current status, challenges, and future directions.
CAR-T therapy for gastrointestinal cancers: current status, challenges, and future directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T 细胞治疗是一种革命性免疫治疗策略,已在血液系统恶性肿瘤中显示疗效。但其用于实体瘤、尤其是胃肠道癌症时,仍面临重大挑战,包括靶抗原选择、肿瘤微环境复杂性以及安全性和毒性问题。本综述概述 CAR-T 治疗食管癌、胃癌、结直肠癌、胰腺癌和肝癌等多种胃肠道癌症的当前进展,并讨论该治疗在这一领域的局限与未来方向。综述重点介绍创新策略,包括新型靶抗原、多特异性 CAR-T 细胞、装甲 CAR-T 细胞和通用型 CAR-T 细胞的开发。这些见解旨在为持续研究提供参考,并推动 CAR-T 细胞治疗胃肠道癌症的发展。
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapeutic strategy that has shown efficacy in hematological malignancies.
However, its application in solid tumors, particularly gastrointestinal cancers, faces significant challenges. These include the selection of target antigens, the complexity of the tumor microenvironment, and safety and toxicity concerns. This review provides a current overview of CAR-T therapy in various gastrointestinal cancers, such as esophageal, gastric, colorectal, pancreatic, and liver cancers.
It discusses the limitations and future directions of CAR-T therapy in this context. This review highlights innovative strategies, including novel target antigens, multispecific CAR-T cells, armored CAR-T cells, and the development of universal CAR-T cells. These insights aim to inform ongoing research and foster advancements in CAR-T therapy for gastrointestinal cancers.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。